187237-37-2 Usage
General Description
Tert-butyl [(5-(aminomethyl)pyridin-2-yl]carbamate is a chemical compound with the molecular formula C13H20N4O2. It is a white solid that is insoluble in water and is used as a reagent in chemical reactions and synthesis. The compound has a tert-butyl group and a pyridin-2-yl carbamate group, which makes it a valuable building block for the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is commonly used as a protective group for amines in organic synthesis and serves as a precursor for the preparation of various compounds with biological activity. Tert-butyl [(5-(aminomethyl)pyridin-2-yl]carbamate is an important intermediate in the production of a wide range of chemical products and has numerous applications in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 187237-37-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,7,2,3 and 7 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 187237-37:
(8*1)+(7*8)+(6*7)+(5*2)+(4*3)+(3*7)+(2*3)+(1*7)=162
162 % 10 = 2
So 187237-37-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H17N3O2/c1-11(2,3)16-10(15)14-9-5-4-8(6-12)7-13-9/h4-5,7H,6,12H2,1-3H3,(H,13,14,15)
187237-37-2Relevant articles and documents
SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1
-
Paragraph 00182-00183, (2021/12/08)
Provided are compounds of Formula (I): (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with TREX1.
THERAPEUTIC INHIBITORY COMPOUNDS
-
, (2015/07/16)
The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.